Change of Director's Interest Notice x 2
Released
Released
Announcement PDF
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX
becomes ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for
the purposes of section 205G of the Corporations Act.
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Part 2 - Change of director's relevant interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Appendix 3Y
Change of Director's Interest Notice
Name of entity Alterity Therapeutics Limited
ABN 37 080 699 065
Name of director Julian Barbaczy
Date of last notice 24 November 2025
Direct or indirect interest Indirect
Nature of indirect interest
(including registered holder)
Vaucluse Investment Holdings Pty Ltd <Jigsaw
Investment A/C> - Director
Date of change 15 June 2026
No. of securities held prior to change NIL
Class UNLISTED OPT EXP 15/06/2031 @ $1.00
Number acquired 2,000,000 - UNLISTED OPT EXP 15/06/2031 @
$1.00
Number disposed NIL
Value/Consideration NIL
No. of securities held after change 2,000,000 - UNLISTED OPT EXP 15/06/2031 @
$1.00
Nature of change Incentive options
Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Part 3 - +Closed period
Appendix 3Y
Change of Director's Interest Notice
No. and class of securities
to which interest related
prior to change
N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
Interest after change N/A
Were the interests in the securities or
contracts detailed above traded during a
+
closed period where prior written clearance
was required?
No.
If so, was prior written clearance provided to
allow the trade to proceed during this period?
N/A
If prior written clearance was provided, on
what date was this provided?
N/A
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX
becomes ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for
the purposes of section 205G of the Corporations Act.
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Appendix 3Y
Change of Director's Interest Notice
Name of entity Alterity Therapeutics Limited
ABN 37 080 699 065
Name of director Lawrence Gozlan
Date of last notice 17 September 2025
Direct or indirect interest (1) Indirect
Nature of indirect interest
(including registered holder)
(1) Montoya Pty Ltd <Buttercup A/C> - Director
Date of change (1.1) N/A
(1.2) 15 June 2026
(1.3) N/A
(1.4) N/A
No. of securities held prior to change (1.1) 1,000,000 - UNLISTED OPT EXP 30/12/2027
@ $0.50
(1.2) NIL - UNLISTED OPT EXP 15/06/2031 @
$1.00
(1.3) 90,910 - FULLY PAID ORDINARY SHARES
(1.4) 30,304 - LISTED OPT EXP 26/02/2027 @
$1.40
Class (1.1) UNLISTED OPT EXP 30/12/2027 @ $0.50
(1.2) UNLISTED OPT EXP 15/06/2031 @ $1.00
(1.3) FULLY PAID ORDINARY SHARES
(1.4) LISTED OPT EXP 26/02/2027 @ $1.40
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Part 2 - Change of director's relevant interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Part 3 - +Closed period
Appendix 3Y
Change of Director's Interest Notice
Number acquired (1.1) NIL
(1.2) 1,000,000 - UNLISTED OPT EXP 15/06/2031
@ $1.00
(1.3) NIL
(1.4) NIL
Number disposed (1.1) NIL
(1.2) NIL
(1.3) NIL
(1.4) NIL
Value/Consideration (1.1) N/A
(1.2) NIL
(1.3) N/A
(1.4) N/A
No. of securities held after change (1.1) 1,000,000 - UNLISTED OPT EXP 30/12/2027
@ $0.50
(1.2) 1,000,000 - UNLISTED OPT EXP 15/06/2031
@ $1.00
(1.3) 90,910 - FULLY PAID ORDINARY SHARES
(1.4) 30,304 - LISTED OPT EXP 26/02/2027 @
$1.40
Nature of change (1.1) N/A
(1.2) Incentive options
(1.3) N/A
(1.4) N/A
Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities
to which interest related
prior to change
N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
Interest after change N/A
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
Appendix 3Y
Change of Director's Interest Notice
Were the interests in the securities or
contracts detailed above traded during a
+
closed period where prior written clearance
was required?
No.
If so, was prior written clearance provided to
allow the trade to proceed during this period?
N/A
If prior written clearance was provided, on
what date was this provided?
N/A
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Share your feedback
Discover